Targeting H3.3 mutated pediatric high grade gliomas – A high throughput screening approach to identify novel therapeutic agents

• DOI: 10.1055/s-0033-1353460
• Publication Date: 2013-11-07T23:30:14Z
• Authors: PD Johann; D Sturm; T Milde; S Bender; S Stark; H Seker-Cin; N Truffaux; J Grill; O Witt; AE Kulozik; P Lichter; J Lewis; S Pfister
• Keywords: Childhood Cancer

Pediatric high grade gliomas (pHGG) are among the most common malignant brain tumors in childhood and account for majority of cancer related mortality this age group. The recent discovery two recurrent mutations tail histone variant H3.3, resulting either a substitution Glycine at position 34 (G34R/V) or Lysine 27 (K27 M), has deepened our understanding tumor entity led to new molecular classification system. However, functional consequences these on biology remain largely unknown. Consequently, no potential drug targets could be delineated genes that differentially regulated K27 M G34R/V mutated tumors.